Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ironwood Pharmaceuti (NQ: IRWD ) 4.350 -0.100 (-2.25%) Streaming Delayed Price Updated: 1:23 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ironwood Pharmaceuti < Previous 1 2 3 Next > Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference May 09, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023 May 08, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance May 04, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old April 24, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call April 20, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences February 27, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results February 16, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old February 13, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call February 02, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance January 09, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference November 22, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance November 03, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call October 20, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation September 06, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference September 01, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand August 04, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call July 21, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022 May 25, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022 May 09, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance May 05, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call April 21, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021 February 17, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call February 03, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance January 10, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference January 05, 2022 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer December 01, 2021 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update November 04, 2021 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. November 04, 2021 From Ironwood Pharmaceuticals, Inc. Via Business Wire More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021 October 25, 2021 From Ironwood Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.